论文部分内容阅读
[目的]探讨康复新液联合埃索美拉唑、莫沙必利治疗糜烂性食管炎(EE)的疗效。[方法]72例EE患者,随机分成2组,治疗组36例,给予康复新液10 ml,3次/d,埃索美拉唑20 mg,2次/d,莫沙必利5 mg,3次/d,口服。对照组36例,给予埃索美拉唑20 mg,2次/d,莫沙必利5 mg,3次/d,口服。于治疗8周后观察症状的缓解情况,同时复查胃镜观察治疗效果。[结果]8周后治疗组症状改善总有效率为94.5%,对照组为88.8%,2组比较差异无统计学意义(P>0.05);胃镜复查治疗组食管炎症总有效率为97.2%,对照组为86.1%,2组比较差异有统计学意义(P<0.05)。[结论]康复新液联合埃索美拉唑、莫沙必利治疗EE临床疗效较好。
[Objective] To investigate the curative effect of Kangfuxin solution combined with esomeprazole and mosapride on erosive esophagitis (EE). [Method] Seventy-two patients with EE were randomly divided into two groups. The treatment group received 36 mg of Kangfuxin solution, 3 times daily, esomeprazole 20 mg twice daily, mosapride 5 mg, 3 times / d, orally. Control group, 36 cases, given esomeprazole 20 mg, 2 times / d, mosapride 5 mg, 3 times / d, orally. After 8 weeks of treatment, the symptom relief was observed, and gastroscopy was used to observe the therapeutic effect. [Results] After 8 weeks, the total effective rate of the symptom improvement was 94.5% in the treatment group and 88.8% in the control group, with no significant difference between the two groups (P> 0.05). The total effective rate of esophageal inflammation in the treatment group was 97.2% The control group was 86.1%, the difference between the two groups was statistically significant (P <0.05). [Conclusion] Kangfuxin combined with esomeprazole and mosapride in treatment of EE has good clinical efficacy.